FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fracture
This is a discussion on FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fracture within the FDA News forum, part of the Industry News and Updates category; More......
|
|||||||
| Register | Help | Members List | Mark Forums Read |
03-10-2010, 03:42 PM
|
|||
|
|||
FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fracture
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA Drug Safety Communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal hea | industry_news | FDA News | 0 | 02-23-2010 12:59 PM |
| Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) | industry_news | FDA News | 0 | 07-16-2009 03:39 PM |
| FDA updates the Early Communication about the Ongoing Safety Review of Bisphosphonates | industry_news | FDA News | 0 | 11-12-2008 11:48 AM |
| Epoetin alfa - Early Communication about an Ongoing Safety Review | industry_news | FDA News | 0 | 09-26-2008 12:42 PM |
| FDA issues an Early Communication about an Ongoing Safety Review for Botox | industry_news | FDA News | 0 | 02-26-2008 03:30 PM |
© 2008 DrugManagementForum™ powered by |
 |